Brenda Mary Duggan, RN Registered Nurse - Case Management Medicare: Not Enrolled in Medicare Practice Location: 195 Kansas Rd, Milbridge, ME 04658 Phone: 207-546-1576 |
Mrs. Adrianne C Vela, Registered Nurse Medicare: Medicare Enrolled Practice Location: 24 School St, Milbridge, ME 04658 Phone: 207-546-2391 |
Katherine Abigail Wallace, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 43 Cottage St, Milbridge, ME 04658 Phone: 207-598-6064 |
News Archive
St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers.
Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.
Because of impairments in their insulin sensitivity, obese individuals demonstrate different brain responses than their normal-weight peers while completing a challenging cognitive task, according to new research by psychologists at The University of Texas at Austin.
The nerve agent sarin causes a deadly overstimulation of the nervous system that can be stopped if treated with an antidote within minutes of poisoning. Today, a ground-breaking study has been published in PNAS, which in detail describes how such a drug works. Researchers at the Swedish Defence Research Agency, Umea University and in Germany are behind the study.
› Verified 9 days ago